Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein (FLAP)-Reference-Cited by-同舟云学术

Pharmacodynamics and Pharmacokinetics of AM103, a Novel Inhibitor of 5-Lipoxygenase-Activating Protein (FLAP)

Published:2010-02-24 Issue:4 Volume:87 Page:437-444
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Bain G,King C D,Rewolinski M,Schaab K,Santini A M,Shapiro D,Moran M,van de Wetering de Rooij S,Roffel A F,Schuilenga-Hut P,Milne G L,Lorrain D S,Li Y,Arruda J M,Hutchinson J H,Prasit P,Evans J F

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Reference35 articles.

1. Biosynthesis and metabolism of leukotrienes

2. The membrane organization of leukotriene synthesis

3. Role of the 5-Lipoxygenase–activating Protein (FLAP) in Murine Acute Inflammatory Responses

4. Altered inflammatory responses in leukotriene-deficient mice.

5. Crystal Structure of Inhibitor-Bound Human 5-Lipoxygenase-Activating Protein

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam;British Journal of Clinical Pharmacology;2024-06-03

2. Quantitation of Oxylipins in Biological Samples, Focusing on Plasma, and Urine;Mass Spectrometry for Lipidomics;2023-03-10

3. Combined Machine Learning and GRID-Independent Molecular Descriptor (GRIND) Models to Probe the Activity Profiles of 5-Lipoxygenase Activating Protein Inhibitors;Frontiers in Pharmacology;2022-03-01

4. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects;Clinical Drug Investigation;2021-09-21

5. Development of a highly sensitive liquid chromatography–mass spectrometry method to quantify plasma leukotriene E4 and demonstrate pharmacological suppression of endogenous 5-LO pathway activity in man;Prostaglandins & Other Lipid Mediators;2020-10